Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Cytokine Modulation Of Amyloid Beta Associated Pathologies In APP Mouse Models Of Alzheimer's Disease Updated On: Jan. 19, 2025
Alzheimer's Disease Research Grant

Cytokine Modulation Of Amyloid Beta Associated Pathologies In APP Mouse Models Of Alzheimer's Disease

a headshot of Dr. Das

Principal Investigator

Pritam Das, PhD

Mayo Clinic Jacksonville

Jacksonville, FL, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$399,999

Active Dates

April 01, 2009 - July 31, 2012

Grant ID

A2009061

Goals

The experiments proposed here will establish an experimental template to study potential disease modifiers, their roles in modulating Alzheimer’s disease (AD) like pathologies and their use in the future design of potential AD therapeutics.

Summary

Alzheimer’s disease (AD) and other related dementia are accompanied by changes in inflammatory markers (cytokines) in the brain. This study will observe how over-expression of specific cytokines affects amyloid beta deposition in an AD mouse model. We hypothesize that immune modulating mediators, like cytokines, play both protective and harmful roles and will help us investigate their role in promoting or reducing amyloid beta associated pathologies in AD. In addition to gaining insight into the cytokines’ roles in altering the pathology, these studies may provide the rationale for development of novel therapeutic approaches for the treatment of AD.

Progress Updates

Over many years, a protein called amyloid beta forms sticky “plaques” in the brains of people with Alzheimer’s disease (AD), ultimately killing the surrounding neurons and causing memory loss and other cognitive problems. Inflammation or excessive action of the brain’s immune cells (called microglia) is another hallmark of the disease. Researchers generally have assumed that inflammation equates with injury and toxicity to neurons, but the relationship between microglia and amyloid plaques remains unclear. To investigate whether a higher degree of brain inflammation would increase the amount of plaques, we used mice that carry AD-causing genetic mutations and produce amyloid plaques in the mouse brain. We then introduced a modified virus to over-produce proteins called cytokines, namely Interleukin-6 (IL-6) and Interferon gamma (IFN-gamma). Both of these cytokines are known to be highly inflammatory, and are prevalent in the brains of patients with AD.

In all experiments examined to date, these cytokines induced robust inflammation and activation of microglia in the brains of mice (IFN-gamma expression in the brain but not IL-6 also caused some neuronal damage). Unexpectedly, expression of both inflammatory cytokines in the brain significantly decreased the amount of amyloid plaques. This is perhaps due to the activation of the microglial cells’ phagocytosis function (the ability to engulf and ingest bacteria or other foreign bodies) and activation of other components of the brain’s immune system (e.g. complement system proteins), helping to prevent and/or remove amyloid-beta deposits from the brain. These exciting results suggest that these inflammatory cytokines may play an important role in restricting amyloid plaque deposition and growth early in the disease process and thus, manipulating and activating the brain’s own microglial cells may hold promise for the future development of therapies for AD.